Research
Print page Print page
Switch language
The Capital Region of Denmark - a part of Copenhagen University Hospital
Published

Budesonide/formoterol maintenance and reliever therapy in adolescent patients with asthma

Research output: Contribution to journalJournal articleResearchpeer-review

  1. Prognostic significance of chronic respiratory symptoms in individuals with normal spirometry

    Research output: Contribution to journalComment/debateResearchpeer-review

  2. European Respiratory Society statement: diagnosis and treatment of pulmonary disease in α1-antitrypsin deficiency

    Research output: Contribution to journalJournal articleResearchpeer-review

  3. Inducible laryngeal obstruction: an official joint European Respiratory Society and European Laryngological Society statement

    Research output: Contribution to journalJournal articleResearchpeer-review

  4. Diagnostic accuracy of a clinical diagnosis of idiopathic pulmonary fibrosis: an international case-cohort study

    Research output: Contribution to journalJournal articleResearchpeer-review

  1. Distinct immune phenotypes in infants developing asthma during childhood

    Research output: Contribution to journalJournal articleResearchpeer-review

  2. Prenatal dietary supplements influence the infant airway microbiota in a randomized factorial clinical trial

    Research output: Contribution to journalJournal articleResearchpeer-review

  3. Virulent coliphages in 1-year-old children fecal samples are fewer, but more infectious than temperate coliphages

    Research output: Contribution to journalJournal articleResearchpeer-review

  4. Fish oil supplementation during pregnancy is protective against asthma/wheeze in offspring

    Research output: Contribution to journalJournal articleResearchpeer-review

View graph of relations

Asthma control is often suboptimal in adolescents, but few studies have evaluated asthma treatments in this population.This post hoc analysis assessed the efficacy and safety of budesonide/formoterol (BUD/FORM) maintenance and reliever therapy (MART) for treatment of persistent asthma in adolescent (age 12-17 years) subgroups within six randomised, double-blind trials. The primary end-point was time to first severe exacerbation. Secondary end-points included number of severe exacerbations, asthma-related symptoms, night-time awakenings, morning peak expiratory flow, forced expiratory volume in 1 s, as-needed medication use and five-item asthma control questionnaire scores.In adolescents (n=1847), BUD/FORM MART was similar to or more effective than comparators across each of the studies in reducing the risk of a first severe exacerbation (hazard ratios (HR) BUD/FORM MART versus comparators 0.15-1.01; pooled HR 0.49, 95% CI 0.34-0.70), with comparable outcomes to the adult subgroups (n=12 197). Similar treatment benefits for BUD/FORM MART were observed for secondary end-points. As-needed medication use was lower with BUD/FORM MART than comparators, and BUD/FORM as-needed use was lower in adolescents than adults. Treatment was well tolerated.This analysis supports the use of BUD/FORM MART in adolescents with persistent asthma, its efficacy and safety being consistent with that reported for adults.

Original languageEnglish
Article number1701688
JournalEuropean Respiratory Journal
Volume51
Issue number1
Pages (from-to)1-13
Number of pages13
ISSN0903-1936
DOIs
Publication statusPublished - Jan 2018

    Research areas

  • Journal Article

ID: 52650069